Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coatomer subunit epsilon (COPE)
- Target
- COPE
- Molecular classification
- Other (component of the coat protein complex I, not a receptor, transporter, enzyme, or ion channel), Cytosolic protein complex subunit, Vesicular transport machinery
01
Overview
Coatomer subunit epsilon (COPE) is one of several subunits (alpha, beta, beta', gamma, delta, epsilon, and zeta) that make up the cytosolic coatomer protein complex I (COPI). COPI mediates retrograde vesicle trafficking between the Golgi apparatus and endoplasmic reticulum as well as intra-Golgi transport. COPE binds to dilysine motifs and is essential for vesicle formation from Golgi membranes, ER-Golgi protein transport, and maintaining organelle integrity. While crucial for cell function, mutations or disruptions in COPE impair vesicle formation, receptor recycling, and cause organelle dysfunction. However, COPE is not currently considered a drug target and does not have direct disease associations beyond rare genetic or transport-related disorders
- Other names
- Coatomer subunit epsilonCoatomer protein complex subunit epsilonEpsilon-COPepsilon-COPEpsilon-coat proteinCOPI coat complex subunit epsiloncoatomer epsilon subunitcoatomer protein complex, subunit epsilon
02
Mechanism of action
Not applicable. No drugs target COPE directly; mechanisms are not characterized
03
Biological functions
Intracellular vesicular transport (Golgi-to-ER retrograde transport)Maintenance of Golgi structural integrityRegulation of LDL receptor endocytic recyclingBudding from Golgi membranesPotential role in lipid droplet morphology regulation and specialized enzyme delivery
04
Disease associations
Peroneal neuropathyGeneral disruption of vesicular trafficking, leading to organelle dysfunction (mutations in COPI components can have broad pathological consequences)No significant, direct roles in cancer, inflammation, neurodegeneration, cardiovascular disease, or infection have been established for COPE itself
05
Safety considerations
Disruption or mutation in COPI complex (including COPE) could interfere with essential cellular protein transport, raising general concerns for cell viability and organelle function if targeted, but these are theoretical; no clinical safety data regarding COPE targeting exists
Beyond the preview
Go deeper on Coatomer subunit epsilon (COPE).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coatomer subunit epsilon (COPE).